Clinical Trial Results:
An open trial to assess the tolerability of AVANZ® Salsola immunotherapy
Summary
|
|
EudraCT number |
2013-001728-20 |
Trial protocol |
ES |
Global end of trial date |
31 Oct 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Jul 2016
|
First version publication date |
21 Jul 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AV-X-02
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02065856 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
ALK-Abelló S.A.
|
||
Sponsor organisation address |
Miguel Fleta, 19, Madrid, Spain, 28037
|
||
Public contact |
Departamento Médico, ALK-Abelló S. A., +34 913276127NA, clinicaltrials@alk.net
|
||
Scientific contact |
Departamento Médico, ALK-Abelló S. A., +34 913276127NA, clinicaltrials@alk.net
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 Oct 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Oct 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Oct 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the tolerability of the up-dosing phase of AVANZ® Salsola kali. The frequency of patients with investigational medicinal product (IMP)-related adverse events (AEs) will be the primary endpoint.
|
||
Protection of trial subjects |
Safety surveillance, use of symptomatic medications allowed. Telephone contact within 48h after IMP administration.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 Jan 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 51
|
||
Worldwide total number of subjects |
51
|
||
EEA total number of subjects |
51
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
51
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Subjects were recruited in Spain | ||||||
Pre-assignment
|
|||||||
Screening details |
The subjects eligible for the trial were adults with a clinical history of Salsola kali pollen induced allergic rhinoconjunctivitis with or without asthma at least one year prior to trial entry, a positive skin prick test (SPT) to Salsola kali pollen, and a positive specific IgE against Salsola kali pollen (≥ IgE class 2; ≥0.70 KU/L). | ||||||
Period 1
|
|||||||
Period 1 title |
Visit 1 (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
Trial is one arm only
|
||||||
Arms
|
|||||||
Arm title
|
ACTIVE TREATMENT | ||||||
Arm description |
AVANZ Salsola kali, updosing treament (5 step) and 1 maintenance dose. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
AVANZ Salsola kali
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Suspension for injection
|
||||||
Routes of administration |
Subcutaneous use
|
||||||
Dosage and administration details |
Weekly administration dose during up-dosing phase until reach the administration dose of 15000 SQ+.
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Visit 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
AVANZ Salsola
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Subjects Treated
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Visit 6
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Subjects who performed visit 6
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
ACTIVE TREATMENT
|
||
Reporting group description |
AVANZ Salsola kali, updosing treament (5 step) and 1 maintenance dose. | ||
Subject analysis set title |
AVANZ Salsola
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Subjects Treated
|
||
Subject analysis set title |
Visit 6
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects who performed visit 6
|
|
|||||||||||||||
End point title |
Frequency of Subject with adverse drug reaction [1] | ||||||||||||||
End point description |
Frequency of patients with adverse drug reactions, local or systemic
|
||||||||||||||
End point type |
Primary
|
||||||||||||||
End point timeframe |
6 weeks
|
||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis provide fro Frequency of Subjects with Adverse Drug Reactions |
|||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Frequency of subjects with systemic reactions | ||||||||
End point description |
Frequency of patients with systemic reactions, based on EAACI classification: Grade I(mild systemic reaction) to IV(anaphylactic shoc)
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
6 weeks
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in IgG4 for Salsola kali | ||||||||||||
End point description |
Increase in IgG4 for Salsola kali from baseline to final
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
6 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Student-t Test | ||||||||||||
Statistical analysis description |
Increase in IgG4 Salsola kali
|
||||||||||||
Comparison groups |
AVANZ Salsola v Visit 6
|
||||||||||||
Number of subjects included in analysis |
100
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.005 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.25
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.1 | ||||||||||||
upper limit |
0.4 | ||||||||||||
Variability estimate |
Standard deviation
|
|
|||||||||||||
End point title |
Change in IgE for Salsola kali | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Visit 1 to visit 6
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Increase in IgE Salsola kali | ||||||||||||
Comparison groups |
AVANZ Salsola v Visit 6
|
||||||||||||
Number of subjects included in analysis |
100
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
8.94
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
5.49 | ||||||||||||
upper limit |
12.4 | ||||||||||||
Variability estimate |
Standard deviation
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Approximately 6 weeks
|
||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
From the first trial related activity after the subject signed the informed consent and until the follow up telephone contact
|
||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.1
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |